78 related articles for article (PubMed ID: 20955827)
1. Antibody dynamics after tick-borne encephalitis and measles-mumps-rubella vaccination in children post early thymectomy.
Zlamy M; Würzner R; Holzmann H; Brandstätter A; Jeller V; Zimmerhackl LB; Prelog M
Vaccine; 2010 Nov; 28(51):8053-60. PubMed ID: 20955827
[TBL] [Abstract][Full Text] [Related]
2. Diminished response to tick-borne encephalitis vaccination in thymectomized children.
Prelog M; Wilk C; Keller M; Karall T; Orth D; Geiger R; Walder G; Laufer G; Cottogni M; Zimmerhackl Lothar B; Stein J; Grubeck-Loebenstein B; Wuerzner R
Vaccine; 2008 Jan; 26(5):595-600. PubMed ID: 18178293
[TBL] [Abstract][Full Text] [Related]
3. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.
Spoulou V; Giannaki M; Vounatsou M; Bakoula C; Grafakos S
Bone Marrow Transplant; 2004 Jun; 33(12):1187-90. PubMed ID: 15077129
[TBL] [Abstract][Full Text] [Related]
4. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine.
Ovsyannikova IG; Pankratz VS; Vierkant RA; Jacobson RM; Poland GA
J Infect Dis; 2006 Mar; 193(5):655-63. PubMed ID: 16453260
[TBL] [Abstract][Full Text] [Related]
5. Humoral and cellular immune response after measles vaccination in Taiwan.
Huang CL; Yang YH; Wang LC; Lin YT; Tsai YY; Chiang BL
J Microbiol Immunol Infect; 2005 Jun; 38(3):169-75. PubMed ID: 15986066
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
Sultana R; Rahman MM; Hassan Z; Hassan MS
Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
[TBL] [Abstract][Full Text] [Related]
7. Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life.
Nair N; Gans H; Lew-Yasukawa L; Long-Wagar AC; Arvin A; Griffin DE
J Infect Dis; 2007 Nov; 196(9):1339-45. PubMed ID: 17922398
[TBL] [Abstract][Full Text] [Related]
8. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
Zäch K; Nicoara C; Germann D; Matter L
Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
[TBL] [Abstract][Full Text] [Related]
9. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.
Davidkin I; Jokinen S; Broman M; Leinikki P; Peltola H
J Infect Dis; 2008 Apr; 197(7):950-6. PubMed ID: 18419470
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
Goh P; Lim FS; Han HH; Willems P
Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
[TBL] [Abstract][Full Text] [Related]
11. JC and BK polyomavirus-specific immunoglobulin G responses in patients thymectomized in early childhood.
Prelog M; Egli A; Zlamy M; Hirsch HH
J Clin Virol; 2013 Nov; 58(3):553-8. PubMed ID: 24055269
[TBL] [Abstract][Full Text] [Related]
12. Detection of secondary mumps vaccine failure by means of avidity testing for specific immunoglobulin G.
Sanz-Moreno JC; Limia-Sánchez A; García-Comas L; Mosquera-Gutiérrez MM; Echevarria-Mayo JE; Castellanos-Nadal A; de Ory-Manchón F
Vaccine; 2005 Sep; 23(41):4921-5. PubMed ID: 15996797
[TBL] [Abstract][Full Text] [Related]
13. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients.
King SM; Saunders EF; Petric M; Gold R
Bone Marrow Transplant; 1996 Apr; 17(4):633-6. PubMed ID: 8722367
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
Vesikari T; Baer M; Willems P
Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
[TBL] [Abstract][Full Text] [Related]
16. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
[TBL] [Abstract][Full Text] [Related]
17. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States.
Gans HA; Yasukawa LL; Alderson A; Rinki M; DeHovitz R; Beeler J; Audet S; Maldonado Y; Arvin AM
J Infect Dis; 2004 Jul; 190(1):83-90. PubMed ID: 15195246
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of antibody responses in tick-borne encephalitis vaccination breakthroughs.
Stiasny K; Holzmann H; Heinz FX
Vaccine; 2009 Nov; 27(50):7021-6. PubMed ID: 19789092
[TBL] [Abstract][Full Text] [Related]
19. Long-term persistence of tick-borne encephalitis antibodies in children 5 years after first booster vaccination with Encepur Children.
Wittermann C; Petri E; Zent O
Vaccine; 2009 Mar; 27(10):1585-8. PubMed ID: 19162115
[TBL] [Abstract][Full Text] [Related]
20. Vaccination against tick-borne encephalitis virus tests specific IgG production ability in patients under immunoglobulin substitution therapy.
Seidel MG; Grohmann E; Sadeghi K; Pollak A; Heitger A; Förster-Waldl E
Vaccine; 2010 Sep; 28(40):6621-6. PubMed ID: 20656033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
